ACAbigail Colley

Abigail Colley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abigail Colley has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    New Therapeutic Cancer Vaccine with Lenalidomide Induces Potent T-cell Immunity and Inhibits HPV E6/E7–Expressing Tumor Growth in Mice

    by Yohannes Gemechu, Sonia Mukherjee, Jeffrey A. Gelfand, Timothy A. Brauns, Ann E. Sluder, Pierre R. Leblanc, Yuki Agarwala, James Adeosun, Abigail Colley, Daiki Sugita, et al.

    Current prophylactic human papillomavirus (HPV) vaccines prevent infection but have limited therapeutic benefit in established HPV-driven malignancies. To address this unmet need, we developed VTX-067, a modular self-assembling therapeutic cancer vaccine consisting of a recombinant Mycobacterium tuberculosis heat shock protein 70–avidin fusion (MAV) noncovalently bound to biotinylated HPV E6/E7 MHC class I– and II–restricted peptide concatemers. MAV is produced in Chinese hamster ovary cells with minimal endotoxin. Assembled VTX-067 is designed to elicit both CD4+ and CD8+ T-cell responses against HPV-associated tumors. In multiple tumor models expressing HPV E6/E7, intradermal vaccination with VTX-067 induced potent and dose-dependent HPV E6/E7–specific CD8+ and CD4+ T-cell responses without evidence of local reactogenicity. Therapeutic vaccination significantly delayed subcutaneous tumor progression, extended survival, and provided durable protection against tumor rechallenge. VTX-067 treatment increased intratumoral CD8+ T-cell infiltration, elevated the CD8:regulatory T-cell ratio, and upregulated a Th1/cytotoxic transcriptional program, including Ifnγ, Tbx21, Stat1, and granzyme B. Depletion of CD8+ T cells eliminated vaccine efficacy, whereas adoptive transfer of VTX-067–primed CD8+ T cells conferred tumor protection in recipient mice. In a cervicovaginal orthotopic model, both intradermal and intramucosal administration generated systemic E6/E7-specific effector responses and sustained control of mucosal tumors. Notably, combining a suboptimal VTX-067 dose with the immunomodulatory agent lenalidomide further enhanced tumor control and survival, demonstrating a potential dose-sparing strategy. These findings establish VTX-067 as a safe, highly immunogenic therapeutic vaccine with CD8+ T cell–dependent antitumor activity and support its clinical development alone or in combination with immune-modulating agents for HPV-associated cancers.